TARGETED RADIOPHARMACEUTICALS AND IMAGING DEVELOPMENT CHALLENGES AND OPPORTUNITIES (HB 2025)

SRIVASTAVA V

ISBN 10: 1837673276 / ISBN 13: 9781837673278

Published by RSC PUBLISHING (NP), 2025

About this Item

Brand New ! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.

Seller Inventory # Cvs 9781837673278

Bibliographic Details

• Title: TARGETED RADIOPHARMACEUTICALS AND IMAGING DEVELOPMENT CHALLENGES AND OPPORTUNITIES (HB 2025)
• Publisher: RSC PUBLISHING (NP)
• Publication Date: 2025
• Language: English
• ISBN 10: 1837673276
• ISBN 13: 9781837673278
• Binding: Hardcover
• Edition: International Edition
• Condition: New

About this title

Synopsis

Targeted radiopharmaceutical therapy (RPT) is emerging as an innovative approach for treating a wide range of cancers.

Almost all radionuclides used in RPT emit photons that can be imaged, enabling non-invasive visualization of the therapeutic agent's biodistribution. The remarkable potential of radiopharmaceutical therapy is now being recognized with recent FDA approval of several RPT drugs and a significant number of drug candidates in clinical development.

This book offers a comprehensive perspective on the different technologies and addresses the critical challenges in developing and commercializing radiopharmaceuticals. It covers various topics, from clinical applications to specific radiopharmaceutical biodistribution, dosimetry, and novel targets in oncology. The chapters provide a cohesive picture of the advances in SPECT/CT and PET/CT imaging, clinical trends in targeted therapies utilizing radioisotopes for cancer imaging, and clinical applications of radiotracers within oncology areas. It also delves into the manufacturing technologies and regulatory and supply logistics required to support the development of the next wave of targeted alpha therapies.

This resource is ideal for postgraduates and researchers in drug discovery and development in radionuclide therapy and imaging in cancer, as well as medical professionals engaged in nuclear medicine and radiology.